CytoDyn Inc.

Yahoo · Oct 26, 2026

CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026

Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including co

Yahoo · Oct 19, 2026

CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO

CytoDyn (OTCMKTS:CYDY) provided an update on its Phase II CLOVER study of leronlimab in metastatic colorectal cancer, highlighting early circulating tumor DNA, or ctDNA, data, preliminary clinical observations and plans for additional studies. The company also announced that CFO Robert Hoffman will

Yahoo · Oct 19, 2026

CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), tod

SeekingAlpha · Oct 19, 2026

CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript